logo
Nauticus Robotics Announces Early Closure of SeaTrepid International Acquisition

Nauticus Robotics Announces Early Closure of SeaTrepid International Acquisition

Nauticus Robotics, Inc. (NASDAQ: KITT, 'Nauticus'), a leading innovator in autonomous subsea robotics and software solutions, today announced ahead of schedule, the final closing of the acquisition of all assets and business of SeaTrepid International, LLC ('SeaTrepid'), an expert in providing subsea robotic services to customers throughout the world.
The early closing reflects the dedication and cooperation of both teams to finalize the transaction. The combined company will begin operations as Nauticus Robotics immediately. Having closed the transaction, the company will now begin the transition and alignment activities which management expects will result in meaningful operational growth.
John Gibson remains the CEO and President of Nauticus Robotics and Bob Christ is the President of SeaTrepid Operations. Steve Walsh is the Vice President of Sales, tasked with bringing the combined offering to the market.
Mr. Gibson stated, 'The dedication and collaboration displayed throughout this process is confirmation that we are an excellent fit. It feels like perfect timing to accelerate the adoption of autonomy in a strong offshore market.'
Mr. Christ added, 'We look forward to what our combined efforts will produce. The market is ready for a strong player bringing automation to existing infrastructure while continuing to push the boundaries of subsea robotic technology.'
Mr. Walsh commented, 'The opportunities for increased offshore safety, vehicle uptime, and efficient operations are enormous. I cannot wait for our team to show existing and potential customers how we will positively impact their operations now and into the future.'
Nauticus Robotics, Inc. develops autonomous robots for the ocean industries. Autonomy requires the extensive use of sensors, artificial intelligence, and effective algorithms for perception and decision allowing the robot to adapt to changing environments. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing of related software to both the commercial and defense business sectors. Nauticus has designed and is currently testing and certifying a new generation of vehicles to reduce operational cost and gather data to maintain and operate a wide variety of subsea infrastructure. Besides a standalone service offering and forward-facing products, Nauticus' approach to ocean robotics has also resulted in the development of a range of technology products for retrofit/upgrading traditional ROV operations and other third-party vehicle platforms. Nauticus' services provide customers with the necessary data collection, analytics, and subsea manipulation capabilities to support and maintain assets while reducing their operational footprint, operating cost, and greenhouse gas emissions, to improve offshore health, safety, and environmental exposure.
About SeaTrepid International
SeaTrepid International, LLC is an applied robotic solutions provider offering support for commercial, public safety, municipal, military and scientific applications. It owns and operates a variety of robotic equipment and sensor suites for both inland and offshore customers worldwide.
Cautionary Language Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the 'Act'), and the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of the safe harbor for forward-looking statements provided by federal securities laws. Such forward-looking statements include but are not limited to: the expected timing of product commercialization or new product releases; customer interest in Nauticus' products; estimated operating results and use of cash; the synergies between Nauticus and SeaTrepid; and Nauticus' use of and needs for capital. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by, or include the words 'believes,' 'estimates,' 'expects,' 'projects,' 'forecasts,' 'may,' 'will,' 'should,' 'seeks,' 'plans,' 'scheduled,' 'anticipates,' 'intends,' or 'continue' or similar expressions. Forward-looking statements inherently involve risks and uncertainties that may cause actual events, results, or performance to differ materially from those indicated by such statements. These forward-looking statements are based on Nauticus' management's current expectations and beliefs, as well as a number of assumptions concerning future events. There can be no assurance that the events, results, or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and Nauticus is not under any obligation and expressly disclaims any obligation, to update, alter, or otherwise revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports which Nauticus has filed or will file from time to time with the Securities and Exchange Commission (the 'SEC') for a more complete discussion of the risks and uncertainties facing the Company and that could cause actual outcomes to be materially different from those indicated in the forward-looking statements made by the Company, in particular the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents filed from time to time with the SEC, including Nauticus' Annual Report on Form 10-K filed with the SEC on April 10, 2024. Should one or more of these risks, uncertainties, or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. The documents filed by Nauticus with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nucor (NUE) Exceeds Market Returns: Some Facts to Consider
Nucor (NUE) Exceeds Market Returns: Some Facts to Consider

Yahoo

time22 minutes ago

  • Yahoo

Nucor (NUE) Exceeds Market Returns: Some Facts to Consider

In the latest market close, Nucor (NUE) reached $124.68, with a +1.75% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 0.63%. Prior to today's trading, shares of the steel company had gained 2.01% over the past month. This has lagged the Basic Materials sector's gain of 4.58% and the S&P 500's gain of 6.29% in that time. The investment community will be closely monitoring the performance of Nucor in its forthcoming earnings report. In that report, analysts expect Nucor to post earnings of $2.21 per share. This would mark a year-over-year decline of 17.54%. Meanwhile, our latest consensus estimate is calling for revenue of $8.28 billion, up 2.55% from the prior-year quarter. For the full year, the Zacks Consensus Estimates project earnings of $7.88 per share and a revenue of $31.48 billion, demonstrating changes of -11.46% and +2.43%, respectively, from the preceding year. Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Nucor. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Nucor currently has a Zacks Rank of #3 (Hold). Investors should also note Nucor's current valuation metrics, including its Forward P/E ratio of 15.54. This valuation marks a premium compared to its industry's average Forward P/E of 10.69. Investors should also note that NUE has a PEG ratio of 0.78 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Steel - Producers industry was having an average PEG ratio of 0.94. The Steel - Producers industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 68, which puts it in the top 28% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nucor Corporation (NUE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

time23 minutes ago

  • Yahoo

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@

Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither
Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither

Yahoo

time28 minutes ago

  • Yahoo

Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither

A highly public feud between Tesla Inc (NASDAQ:TSLA) CEO Elon Musk and President Donald Trump took the world by storm last week and sent shares of the electric vehicle company lower. As the feud continues on, here's a look at where Benzinga readers stand. What Happened: A back-and-forth between Musk and Trump across social media platforms saw the two well-known individuals escalate a feud related to differences on the "Big Beautiful Bill." Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — The feud comes after Musk left his White House position working for the Department of Government Efficiency to spend more time working on his other companies, such as Tesla. Benzinga recently asked readers who they side with in the battle, which includes Musk criticizing the new debt the country will take on if the bill that Trump supports is passed by Congress. "In the feud between Donald Trump and Elon Musk, who are you more likely to publicly support?" Benzinga asked. Here are the results: Neither: 44% Elon Musk: 25% Donald Trump: 17% Both: 14% The poll found that a near majority said they would publicly support neither Trump or Musk in the feud between former friends. Of the two well-known candidates, Musk received the largest support with 25% of the poll, ranking ahead of Trump at 17%.Why It's Important: Over the weekend, the battle between Musk and Trump minimized some with the Tesla CEO deleting some of his tweets that brought some claims against the current president. Tweets about ending the SpaceX Dragon program were also deleted. A battle between Trump and Musk over the long run could see many losers, including the country's space program and the launch of robotaxis, with Musk a leader in both sectors and Trump able to slow down progress made by the billionaire. Tesla stock saw its largest one-day market capitalization drop last week on the heels of the feud. Tesla stock trades up 1.61% at $299.72 at publication on Monday versus a 52-week trading range of $167.42 to $488.54. The stock has fallen 15% over the last five days and is down 22% year-to-date in 2025. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? The study was conducted by Benzinga from June 5, 2025, through June 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 259 adults. Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither originally appeared on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store